Mylan has launched the Sirdupla salmeterol xinafoate/fluticasone propionate MDI, its bioequivalent version of GlaxoSmithKline’s Seretide (Advair) Evohaler, for the treatment of asthma in the UK, the company announced. The product, which is being marketed in 125/25 mcg and 250/25 mcg versions, is manufactured by 3M Drug Delivery Systems.
Mylan President Rajiv Malik said, “Mylan is excited to be the first company to offer adult asthma patients in the UK the generic version of Seretide Evohaler, delivering on our mission to increase access to high quality medicine. Sirdupla represents a significant advancement for the company that both strengthens our respiratory portfolio and pipeline and further demonstrates our ability to successfully execute on one of our key strategic growth drivers.”
3MDDS President and General Manager Cindy Kent commented, “3M will fill, assemble and package Sirdupla at 3M’s manufacturing facility in Loughborough, UK. By partnering with Mylan, 3M has taken an important step forward in the generics space. This partnership combines 3M’s expertise in inhalation drug development and manufacturing with Mylan’s leadership position in the global generics market, including expertise in commercializing complex respiratory products.”
Read the Mylan press release.
